Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?
作者信息
Ito Tetsuhide, Igarashi Hisato, Jensen Robert T
出版信息
Pancreas. 2012 May;41(4):505-7. doi: 10.1097/MPA.0b013e318249a92a.
Abstract
摘要
相似文献
1
Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?血清胰抑素：长期以来一直在寻找的用于神经内分泌肿瘤的通用、敏感、特异的肿瘤标志物？
Pancreas. 2012 May;41(4):505-7. doi: 10.1097/MPA.0b013e318249a92a.
2
A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.一项关于慢性质子泵抑制剂使用对人体血浆生物标志物水平影响的前瞻性评估。
Pancreas. 2012 May;41(4):508-11. doi: 10.1097/MPA.0b013e318243a0b6.
3
Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.嗜铬粒蛋白B与嗜铬粒蛋白A作为生物标志物在日本胰腺神经内分泌肿瘤患者中的效用比较
Jpn J Clin Oncol. 2017 Jun 1;47(6):520-528. doi: 10.1093/jjco/hyx032.
4
Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients.胃泌素瘤患者血清中的嗜铬粒蛋白A和胰抑制素样免疫反应性
Acta Oncol. 1993;32(2):161-5. doi: 10.3109/02841869309083906.
5
Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.开发一种高度敏感和特异的羧基末端人胰高糖素原检测方法，以监测神经内分泌肿瘤的行为。
Pancreas. 2010 Jul;39(5):611-6. doi: 10.1097/MPA.0b013e3181c68d7a.
6
Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours.对类癌肿瘤和胰腺内分泌肿瘤患者的血浆及尿液中的嗜铬粒蛋白A、嗜铬粒蛋白B（分泌粒蛋白I）、嗜铬粒蛋白C（分泌粒蛋白II）和胰抑制素进行测量。
J Endocrinol. 1995 Jan;144(1):49-59. doi: 10.1677/joe.0.1440049.
7
A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.一种多分析物聚合酶链反应血液检测在神经内分泌肿瘤检测方面优于单一分析物酶联免疫吸附测定法（嗜铬粒蛋白A、胰腺抑制素、神经激肽A）。
Endocr Relat Cancer. 2014 Aug;21(4):615-28. doi: 10.1530/ERC-14-0190.
8
Serum pancreastatin: the next predictive neuroendocrine tumor marker.血清胰多肽原：下一个预测神经内分泌肿瘤标志物。
J Surg Oncol. 2013 Aug;108(2):126-8. doi: 10.1002/jso.23359. Epub 2013 Jun 15.
9
A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.进餐试验可提高嗜铬粒蛋白A作为神经内分泌肿瘤标志物的特异性。
Tumour Biol. 2010 Oct;31(5):373-80. doi: 10.1007/s13277-010-0045-5. Epub 2010 May 18.
10
Serum peptide profiles in patients with carcinoid tumors.类癌肿瘤患者的血清肽谱。
Am J Surg. 2003 Jul;186(1):28-31. doi: 10.1016/s0002-9610(03)00115-6.
引用本文的文献
1
Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors.类癌肿瘤的新兴免疫治疗和诊断方法。
Molecules. 2023 Feb 22;28(5):2047. doi: 10.3390/molecules28052047.
2
Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.循环神经内分泌肿瘤生物标志物：过去、现在与未来
J Clin Med. 2022 Sep 21;11(19):5542. doi: 10.3390/jcm11195542.
3
Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.晚期胰腺神经内分泌肿瘤患者接受药物/放射/肝脏靶向抗肿瘤治疗后耐药性疾病的预测因素：最新进展与争议
Cancers (Basel). 2022 Feb 28;14(5):1250. doi: 10.3390/cancers14051250.
4
Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.胰腺神经内分泌肿瘤的总生存和手术结局的预后和预测因素：最新进展和争议。
Expert Rev Anticancer Ther. 2019 Dec;19(12):1029-1050. doi: 10.1080/14737140.2019.1693893. Epub 2019 Nov 27.
5
Biochemical Testing in Neuroendocrine Tumors.神经内分泌肿瘤的生化检测。
Endocrinol Metab Clin North Am. 2017 Sep;46(3):669-677. doi: 10.1016/j.ecl.2017.04.004. Epub 2017 Jun 12.
6
Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.嗜铬粒蛋白B与嗜铬粒蛋白A作为生物标志物在日本胰腺神经内分泌肿瘤患者中的效用比较
Jpn J Clin Oncol. 2017 Jun 1;47(6):520-528. doi: 10.1093/jjco/hyx032.
7
Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.日本在胰腺神经内分泌肿瘤的诊断和治疗方面的进展。
J Gastroenterol. 2017 Jan;52(1):9-18. doi: 10.1007/s00535-016-1250-9. Epub 2016 Aug 18.
8
Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.嗜铬粒蛋白A、胰多肽、胰高血糖素和胃泌素在1型多发性内分泌腺瘤患者胰腺神经内分泌肿瘤诊断及随访中的应用
Clin Endocrinol (Oxf). 2016 Sep;85(3):400-7. doi: 10.1111/cen.13119. Epub 2016 Jun 30.
9
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.《欧洲神经内分泌肿瘤学会功能性胰腺神经内分泌肿瘤和非功能性胰腺神经内分泌肿瘤患者管理共识指南更新》
Neuroendocrinology. 2016;103(2):153-71. doi: 10.1159/000443171. Epub 2016 Jan 5.
10
Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.血清嗜铬粒蛋白A对日本胰腺神经内分泌肿瘤患者是一种有用的标志物。
Cancer Sci. 2014 Nov;105(11):1464-71. doi: 10.1111/cas.12533. Epub 2014 Oct 18.
本文引用的文献
1
A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.一项关于慢性质子泵抑制剂使用对人体血浆生物标志物水平影响的前瞻性评估。
Pancreas. 2012 May;41(4):508-11. doi: 10.1097/MPA.0b013e318243a0b6.
2
Management of early gastrointestinal neuroendocrine neoplasms.早期胃肠道神经内分泌肿瘤的管理
World J Gastrointest Endosc. 2011 Jul 16;3(7):133-9. doi: 10.4253/wjge.v3.i7.133.
3
The Zollinger-Ellison syndrome and mismeasurement of gastrin.卓-艾综合征与胃泌素的误测。
Gastroenterology. 2011 May;140(5):1444-53. doi: 10.1053/j.gastro.2011.01.051. Epub 2011 Mar 23.
4
Effect of proton-pump inhibitor therapy on serum chromogranin a level.质子泵抑制剂治疗对血清嗜铬粒蛋白 A 水平的影响。
Digestion. 2011;84(1):22-8. doi: 10.1159/000321535. Epub 2011 Feb 8.
5
Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.嗜铬粒蛋白 A——神经内分泌肿瘤疾病中的生物学功能和临床应用。
Ann Surg Oncol. 2010 Sep;17(9):2427-43. doi: 10.1245/s10434-010-1006-3. Epub 2010 Mar 9.
6
Granins and granin-related peptides in neuroendocrine tumours.神经内分泌肿瘤中的嗜铬粒蛋白及嗜铬粒蛋白相关肽
Regul Pept. 2010 Nov 30;165(1):12-20. doi: 10.1016/j.regpep.2010.02.011. Epub 2010 Mar 6.
7
Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.开发一种高度敏感和特异的羧基末端人胰高糖素原检测方法，以监测神经内分泌肿瘤的行为。
Pancreas. 2010 Jul;39(5):611-6. doi: 10.1097/MPA.0b013e3181c68d7a.
8
A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours.生长抑素类似物治疗后循环中胰抑制素迅速升高与神经内分泌肿瘤患者的不良生存相关。
Ann Clin Biochem. 2008 Nov;45(Pt 6):560-6. doi: 10.1258/acb.2008.008033. Epub 2008 Sep 9.
9
Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.改善胃肠胰神经内分泌肿瘤管理的优先事项。
J Natl Cancer Inst. 2008 Sep 17;100(18):1282-9. doi: 10.1093/jnci/djn275. Epub 2008 Sep 9.
10
Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.血浆嗜铬粒蛋白A作为转移性内分泌胃肠胰腺肿瘤患者生存的标志物。
Clin Gastroenterol Hepatol. 2008 Jul;6(7):820-7. doi: 10.1016/j.cgh.2008.02.052. Epub 2008 Jun 10.
Zotero 插件